Further pharmacogenetic investigations should expand the focus to include other functional polymorphisms of the SLC6A2, given the increased use of noradrenergic drugs in the treatment of ADHD symptoms [37], in order to better understand the role of genetic variation in a good vs. poor response to drug treatment for ADHD. Here, SLC6A2 is linked to attention deficit-hyperactivity disorder.